RET Fusion & Mutation Cancer Market Size & Trends (2026-2031)

Market growth is driven by increasing adoption of precision oncology, expanding genomic testing, growing use of selective RET inhibitors, and rising integration of biomarker-driven cancer treatment.

Selective RET inhibitors are preferred because they offer higher specificity, improved efficacy, and lower off-target toxicity compared to older multikinase inhibitors.

Molecular diagnostics are essential because therapy eligibility depends on identifying RET gene alterations through validated genomic testing methods.

Key challenges include limited access to advanced molecular diagnostics, small patient populations, reimbursement variability, and acquired resistance mutations.

Key companies include Eli Lilly and Company, Blueprint Medicines Corporation, F. Hoffmann-La Roche Ltd, Genentech, Inc., and Exelixis, Inc..